Compare · AMGN vs HUMA
AMGN vs HUMA
Side-by-side comparison of Amgen Inc. (AMGN) and Humacyte Inc. (HUMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and HUMA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $186.59B, about 609.0x HUMA ($306.4M).
- Over the past year, AMGN is up 19.1% and HUMA is down 46.4% - AMGN leads by 65.5 points.
- AMGN has been more active in the news (19 items in the past 4 weeks vs 7 for HUMA).
- AMGN has more recent analyst coverage (25 ratings vs 11 for HUMA).
- Company
- Amgen Inc.
- Humacyte Inc.
- Price
- $345.61-1.12%
- $1.38+1.85%
- Market cap
- $186.59B
- $306.4M
- 1M return
- +5.03%
- +27.31%
- 1Y return
- +19.15%
- -46.39%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2020
- News (4w)
- 19
- 7
- Recent ratings
- 25
- 11
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
Latest HUMA
- Humacyte Inc. filed SEC Form 8-K: Other Events
- Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
- Director Sebelius Kathleen bought $50,000 worth of shares (56,818 units at $0.88), increasing direct ownership by 62% to 148,025 units (SEC Form 4)
- Director Constantino Michael T. bought $9,840 worth of shares (11,000 units at $0.89), increasing direct ownership by 33% to 43,950 units (SEC Form 4)
- CFO and Chief Corp. Dev. Off Sander Dale A. sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 267,213 units (SEC Form 4) to satisfy tax liability
- Chief Medical Officer Parikh Shamik J sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 272,713 units (SEC Form 4) (for withholding tax)
- Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
- SEC Form S-8 filed by Humacyte Inc.
- SEC Form 10-Q filed by Humacyte Inc.
- Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update